Antigenic distinctions between malignant and normal cells are the key problem of cancer immunology. The researches in this direction allow clarifying not only the mechanism of cell malignancy, tumor progression and the way it escapes from immuno-surveillance of an organism, but also introduce a substantial contribution in clinical tumor immunology and immunotherapy. To date, a lot of the facts about antigens of the tumor cells are accumulated. In the introduced review are given classification and description of tumor antigens. We propose to unite tumor-associated antigens which are characteristic of normal nonhomologous to tumor tissues in a group of heteroorganic antigens. According to definition, such well-known antigens as cancer/testis antigens and onconeural antigens are included in this group.
Download full-text PDF |
Source |
---|
Lab Anim
January 2025
Department of Physiology, Faculty of Medicine, University of Colombo, Sri Lanka.
The immunogenicity of rabies vaccines is commonly measured by serological testing, which includes measuring rabies virus-neutralising antibody titre levels in the serum. Apart from humoral immunity, cellular immunity measurements are also helpful in assessing the immunogenicity and efficacy of rabies vaccinations. Recently, there has been an increased emphasis on cellular immunity measurements against rabies in humans and animals.
View Article and Find Full Text PDFDermatitis
January 2025
Department of Dermatology, University of California, San Francisco, California, USA.
Toluene-2,5-diamine sulfate (PTDS), also known as toluene diamine sulfate or 2,5-diaminotoluene sulfate, is an aromatic amine that can be used as a paraphenylenediamine (PPD) hair dye alternative. Patients may develop contact allergy to PTDS, and it is often omitted from standard patch test screening series, possibly leading to underdiagnosis. The American Contact Dermatitis Society named PTDS the Allergen of the Year for 2025, aiming to raise awareness of its dual role as both an allergen and an alternative for some PPD-allergic individuals.
View Article and Find Full Text PDFInflamm Res
January 2025
Departamento de Biomedicina - Unidade de Farmacologia e Terapêutica, Faculdade de Medicina da Universidade do Porto (FMUP), Rua Dr. Plácido da Costa, S/N, Edifício Poente, Piso 3, 4200-450, Porto, Portugal.
Background And Aims: Endocan has been scarcely explored in COVID-19, especially regarding its modulation by veno-venous extracorporeal membrane oxygenation (VV-ECMO), hypertension or previous renin-angiotensin-aldosterone system (RAAS) inhibitors treatment. We compared endocan and other endotheliitis markers in hospitalized COVID-19 patients and assessed their modulation by VV-ECMO, hypertension and previous RAAS inhibitors treatment.
Material And Methods: Serum endocan, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and E-selectin were measured in "severe" (n = 27), "critically ill" (n = 17) and "critically ill on VV-ECMO" (n = 17) COVID-19 patients at admission, days 3-4, 5-8 and weekly thereafter, and in controls (n = 23) at a single time point.
Amino Acids
January 2025
Tissue Engineering and Regenerative Medicine Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.
In recent years, the use of cationic peptides as alternative drugs with anticancer activity has received attention. In this study, the targeted release of curcumin (Cur) and CM11 peptide alone and together against hepatocellular carcinoma (HCC) was evaluated using chitosan nanoparticles (CS NPs) coated with Pres1 that target the SB3 antigen of HCC cells (PreS1-Cur-CM11-CS NPs). SB3 protein is the specific antigen of HCC and the PreS1 peptide is a part of the hepatitis B antigen, which can specifically bind to the SB3 protein.
View Article and Find Full Text PDFAbdom Radiol (NY)
January 2025
Departmet of Urology, Medical Academy, Lithuanian University of Health Sciences, Mickeviciaus str. 9, Kaunas, 44307, Lithuania.
Objectives: This study aimed to investigate the accuracy of multiparametric magnetic resonance imaging (mpMRI), genetic urinary test (GUT), and prostate cancer prevention trial risk calculator version 2.0 (PCPTRC2) for the clinically significant prostate cancer (csPCa) diagnostic in biopsy-naïve patients.
Materials And Methods: In a single center study between 2021 and 2024 participants underwent prostate mpMRI, GUT, and ultrasound (US) guided biopsy.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!